首页> 外文期刊>Diabetes technology & therapeutics >Evaluation of an Artificial Pancreas with Enhanced Model Predictive Control and a Glucose Prediction Trust Index with Unannounced Exercise
【24h】

Evaluation of an Artificial Pancreas with Enhanced Model Predictive Control and a Glucose Prediction Trust Index with Unannounced Exercise

机译:评估具有增强模型预测控制的人工胰腺及葡萄糖预测信任指数与未经发布的运动

获取原文
获取原文并翻译 | 示例
           

摘要

Background: We investigated the safety and efficacy of the addition of a trust index to enhanced Model Predictive Control (eMPC) Artificial Pancreas (AP) that works by adjusting the responsiveness of the controller's insulin delivery based on the confidence intervals around predictions of glucose trends. This constitutes a dynamic adaptation of the controller's parameters in contrast with the widespread AP implementation of individualized fixed controller tuning. Materials and Methods: After 1 week of sensor-augmented pump (SAP) use, subjects completed a 48-h AP admission that included three meals/day (carbohydrate range 29-57g/meal), a 1-h unannounced brisk walk, and two overnight periods. Endpoints included sensor glucose percentage time 70-180, 70, 180mg/dL, number of hypoglycemic events, and assessment of the trust index versus standard eMPC glucose predictions. Results: Baseline characteristics for the 15 subjects who completed the study (meanSD) were age 46.1 +/- 17.8 years, HbA1c 7.2%+/- 1.0%, diabetes duration 26.8 +/- 17.6 years, and total daily dose (TDD) 35.5 +/- 16.4U/day. Mean sensor glucose percent time 70-180mg/dL (88.0%+/- 8.0% vs. 74.6%+/- 9.4%), 70mg/dL (1.5%+/- 1.9% vs. 7.8%+/- 6.0%), and number of hypoglycemic events (0.6 +/- 0.6 vs. 6.3 +/- 3.4), all showed statistically significant improvement during AP use compared with the SAP run-in (P0.001). On average, the trust index enhanced controller responsiveness to predicted hyper- and hypoglycemia by 26% (P0.005). Conclusions: In this population of well-controlled patients, we conclude that eMPC with trust index AP achieved nearly 90% time in the target glucose range. Additional studies will further validate these results.
机译:背景:我们调查了增强模型预测控制(EMPC)人工胰腺(EMPC)的安全性和功效来通过根据葡萄糖趋势预测的置信区间调整控制器的胰岛素递送的响应性来调整控制的模型预测控制(EMPC)人工胰腺(AP)。与个性化固定控制器调谐的广泛AP实现相比,这构成了控制器参数的动态自适应。材料和方法:传感器增强泵(SAP)使用1周后,受试者完成了48小时的AP入场,其中包括三餐/天(碳水化合物范围29-57g /膳食),一个1-H未经发布的轻快步行,两个过夜。终点包括传感器葡萄糖百分比时间70-180,70,& 180mg / dl,低血糖事件的数量,以及信托指数的评估与标准EMPC葡萄糖预测。结果:完成研究(手段)的15个受试者的基线特征为46.1 +/- 17.8岁,HBA1C 7.2%+ / - 1.0%,糖尿病持续时间26.8 +/- 17.6岁,以及总日剂量(TDD)35.5 +/- 16.4u /天。平均传感器葡萄糖百分比70-180mg / dL(88.0%+ / - 8.0%vs.74.6%+ / - 9.4%),70mg / dl(1.5%+ / - 1.9%与7.8%+ / - 6.0 %)和低血糖事件数量(0.6 +/- 0.6对6.3 +/- 3.4),与SAP运行相比,AP使用期间显示出统计学上显着的改善(P <0.001)。平均而言,信任指数增强了控制器响应于预测的超血糖和低血糖26%(P <0.005)。结论:在该良好控制的患者中,我们得出结论,具有信任指数AP的EMPC在目标葡萄糖范围内实现了近90%的时间。其他研究将进一步验证这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号